Migraine, Vascular Risk, and Cardiovascular Events in Women: Prospective Cohort Study

Citation
Kurth, Tobias, Markus Schurks, Giancarlo Logroscino, J. Michael Gaziano, and Julie E. Buring. 2008. Migraine, vascular risk, and cardiovascular events in women: Prospective cohort study. BMJ 337: a636.

Published Version
doi:10.1136/bmj.a636

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:5129841

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
ABSTRACT

Objectives To evaluate whether the association between migraine with aura and increased risk of cardiovascular disease is modified by vascular risk groups as measured by the Framingham risk score for coronary heart disease.

Design Prospective cohort study.

Setting Women’s health study, United States.

Participants 27,519 women who were free from cardiovascular disease at baseline with available information on the Framingham risk score and migraine status.

Main outcome measures Time to major cardiovascular disease event (non-fatal myocardial infarction, non-fatal ischaemic stroke, death from ischaemic cardiovascular disease), myocardial infarction, and ischaemic stroke.

Results At baseline, 3577 (13.0%) women reported active migraine, of whom 1418 (39.6%) reported migraine with aura. During 11.9 years of follow-up, there were 697 cardiovascular disease events. We stratified participants based on 10 year risk of coronary heart disease estimated from the Framingham risk score (5%, 2-4%, 5-9%, and ≥10%). Compared with women without migraine, the age adjusted hazard ratios in women with active migraine with aura were 1.93 (95% confidence interval 1.45 to 2.56) for major cardiovascular disease, 1.80 (1.16 to 2.79) for ischaemic stroke, and 1.94 (1.27 to 2.95) for myocardial infarction. When stratified by Framingham risk score, the association between migraine with aura and major cardiovascular disease was strongest in the lowest risk score group. There was a diametric association pattern for ischaemic stroke and myocardial infarction. Compared with women without migraine, the age adjusted hazard ratios in women who reported migraine with aura in the lowest Framingham risk score group were 3.88 (1.87 to 8.08) for ischaemic stroke and 1.29 (0.40 to 4.21) for myocardial infarction. Hazard ratios in women with migraine with aura in the highest Framingham risk score group were 1.00 (0.24 to 4.14) for ischaemic stroke and 3.34 (1.50 to 7.46) for myocardial infarction. Women with migraine without aura were not at increased risk of ischaemic stroke or myocardial infarction in any of the Framingham risk score groups.

Conclusion The association between migraine with aura and cardiovascular disease varies by vascular risk status.

Information on history of migraine and vascular risk status might help to identify women at increased risk for specific future cardiovascular disease events.

Trial registration Clinical trials NCT00000479.
cardiovascular disease that depends on the underlying vascular risk status is important for clinicians as it might help to identify individuals at increased risk of future cardiovascular disease events. We evaluated whether the association between migraine with aura and overall and specific cardiovascular disease events differed according to vascular risk status, as measured by the Framingham risk score.16

METHODS

Study population

We carried out a prospective cohort study among participants in the women’s health study, a completed trial designed to test the benefits and risks of low dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer among apparently healthy women. The design and results have been described in detail previously.17 18 Briefly, 39 876 US female health professionals aged ≥45 at study entry (1992-5) and without a history of cardiovascular disease, cancer, or other major illnesses, were randomly assigned to aspirin (100 mg on alternate days), vitamin E (600 IU on alternate days), both active agents, or both placebos. Baseline information was self reported and was collected by a mailed questionnaire that asked about many cerebrovascular risk factors and lifestyle variables. Twice in the first year and yearly thereafter, participants were sent follow-up questionnaires asking about study outcomes, personal characteristics, medical history, and health habits. For this analysis, we included follow-up information from study entry to 31 March 2007. As of this date, follow-up was 97% complete.

Before randomisation, blood samples were collected in tubes containing EDTA from 28 345 participating women and stored in vapour phase liquid nitrogen (−170°C). Samples were analysed for lipids and inflammatory biomarkers. Total cholesterol, high density lipoprotein cholesterol, and directly obtained low density lipoprotein cholesterol were assayed with reagents from Roche Diagnostics (Basel, Switzerland) and Genzyme (Cambridge, MA). Cholesterol analyses could be performed on 27 939 of the blood samples.

Assessment of migraine

On the baseline questionnaire participants were asked: “Have you ever had migraine headaches?” and “In the past year, have you had migraine headaches?” From this information, we categorised women into “no history of migraine” and “any history of migraine.” We also distinguished between “active migraine,” which included women with self reported migraine in the year before they completed the baseline questionnaire, and “prior migraine,” which included women who reported ever having had a migraine but none in the year before they completed the questionnaire. Those participants who reported active migraine were asked about migraine specific features. In the women’s health study,11 19 we have previously shown good agreement with 1988 International Headache Society (IHS) criteria for migraine.20 Specifically, we showed that among those who provided a blood sample and reported active migraine, over 83% fulfilled all but one IHS criterion (code 1.7, migrainous disorder) and over 46% fulfilled all IHS criteria for migraine (code 1.1 migraine without aura).11

Participants who reported active migraine were further asked whether they had an “aura or any indication a migraine is coming.” Responses were used to classify women who reported active migraine into active migraine with aura and active migraine without aura.

Framingham risk score

We used the Framingham risk score, which predicts the 10 year risk of coronary heart disease, as defined by the National Cholesterol Education Program,16 to classify participating women into vascular risk classes. This score assigns points for age, total cholesterol, high density lipoprotein cholesterol, smoking, and systolic blood pressure stratified by treatment for hypertension. The points for each individual component are summed and categorised into groups of 10 year risk of coronary heart disease of ≤1% (≤12 points), 2-4% (13-16 points), 5-9% (17-19 points), and ≥10% (≥20 points), as in a previous report of the women’s health study.21

Outcome ascertainment

All participants were followed up for the occurrence of a major ischaemic vascular event, a combined end point defined as the first of any of non-fatal ischaemic stroke, non-fatal myocardial infarction, or ischaemic cardiovascular death. In addition, we evaluated any first myocardial infarction, ischaemic stroke, coronary revascularisation procedure, and angina. There were too few cases of cardiovascular death to perform meaningful stratified analyses. Medical records were obtained for all reported cardiovascular end points except angina and reviewed by an end points committee of physicians. Stroke was confirmed if the participant had a new focal neurological deficit of sudden onset that persisted for more than 24 hours and was then classified as ischaemic, haemorrhagic, or undefined, with excellent agreement between observers.22 For this report, we included only cases of ischaemic stroke and censored participants with other subtypes of stroke at the time of event. The occurrence of myocardial infarction was confirmed if symptoms met World Health Organization criteria and if the event was associated with abnormal levels of cardiac enzymes or abnormal results on electrocardiography. Cardiovascular deaths were confirmed by autopsy reports, death certificates, medical records, and information obtained from next of kin or family members.

Statistical analyses

Of the 27 939 women with completed blood assays, we excluded 79 with missing information on migraine status, 321 with missing information on Framingham risk score, and 20 who reported angina before they
received the baseline questionnaire, leaving 27,519 women free from cardiovascular disease or angina at study entry for this analysis. We compared the baseline characteristics of participants, with respect to their migraine status, using analysis of covariance for continuous measurements adjusted for age. We used direct standardisation to adjust categorical variables for age in 5 year increments.

We used multinominal logistic regression models to calculate prevalence odds ratios and 95% confidence intervals of the association between migraine and migraine aura status with Framingham risk score categories, adjusting for age. We used age adjusted Cox proportional hazards models to evaluate the association between migraine and migraine aura status with risks of incident cardiovascular disease or angina.

We ran stratified analyses on categories of predicted 10 year risk of coronary heart disease based on Framingham risk score (≤1%, 2-4%, 5-9%, and ≥10%). In addition, we ran stratified analyses of the association between migraine and the various outcomes for individual components of the Framingham risk score (age, systolic blood pressure, smoking, total cholesterol, and high density lipoprotein cholesterol). All analyses were performed with SAS version 9.1 (SAS, Cary, NC); P values were two tailed and P<0.05 was considered significant.

RESULTS

Of the 27,519 participants, 5074 (18.4%) women reported any history of migraine, and 3577 (13.0%) reported active migraine (migraine in the year before completing baseline questionnaire).

Table 1 | Age adjusted baseline characteristics in 27,519 women according to migraine status in women’s health study. Figures are percentages* of women unless stated otherwise

| Characteristics                        | No migraine history | Active migraine with aura | Active migraine without aura | Prior migraine† | P value‡ |
|---------------------------------------|---------------------|---------------------------|-----------------------------|-----------------|---------|
| No of participants                    | 22,445              | 1418                      | 2159                        | 1497            |         |
| Mean (SE) age (years)                 | 54.9 (0.05)         | 53.2 (0.19)               | 52.6 (0.15)                 | 55.5 (0.18)     | <0.001  |
| Mean (SE) Framingham risk score      | 12.2 (0.02)         | 12.3 (0.09)               | 12.3 (0.07)                 | 12.7 (0.08)     | <0.001  |
| Framingham estimate of 10 year risk of coronary heart disease: |         |                           |                             |                 |         |
| ≤1                                    | 54.4                | 53.6                      | 54.3                        | 48.9            | <0.001  |
| 2-4                                   | 30.4                | 30.3                      | 30.8                        | 32.3            |         |
| 5-9                                   | 11.4                | 11.8                      | 11.5                        | 13.2            |         |
| ≥10                                   | 3.9                 | 4.3                       | 3.5                         | 5.6             |         |
| Mean (SE) total cholesterol (mmol/l)  | 5.46 (0.002)        | 5.52 (0.03)               | 5.51 (0.02)                 | 5.56 (0.03)     | 0.001   |
| Mean (SE) HDL cholesterol (mmol/l)    | 1.39 (0.003)        | 1.37 (0.01)               | 1.38 (0.008)                | 1.36 (0.01)     | 0.001   |
| Mean (SE) systolic blood pressure (mm Hg) | 123.6 (0.09)       | 123.5 (0.35)              | 124.4 (0.29)                | 124.6 (0.34)    | 0.001   |
| Smoking:                              |                     |                           |                             |                 |         |
| Never                                 | 51.2                | 52.4                      | 56.2                        | 50.5            | 0.03    |
| Past                                  | 37.0                | 37.3                      | 34.5                        | 35.5            |         |
| Current                               | 11.8                | 10.3                      | 9.3                         | 14.1            |         |
| History of hypertension§              | 24.7                | 25.6                      | 26.1                        | 30.5            | <0.001  |
| History of diabetes                   | 2.5                 | 1.8                       | 1.6                         | 2.6             | 0.23    |
| Mean (SE) BMI                         | 25.9 (0.03)         | 25.8 (0.13)               | 26.2 (0.11)                 | 26.1 (0.13)     | 0.02    |
| Alcohol consumption:                  |                     |                           |                             |                 |         |
| Rarely/never                          | 43.5                | 48.2                      | 47.4                        | 45.1            | <0.001  |
| 1-3 drinks/month                      | 13.1                | 12.9                      | 15.4                        | 14.3            |         |
| 1-6 drinks/week                       | 32.7                | 30.5                      | 30.0                        | 30.4            |         |
| ≥1 drink/day                          | 10.8                | 8.4                       | 7.2                         | 10.3            |         |
| Physical activity:                    |                     |                           |                             |                 | <0.001  |
| Rarely/never                          | 36.9                | 38.0                      | 39.4                        | 39.2            |         |
| <1/week                               | 19.2                | 20.4                      | 21.7                        | 20.2            |         |
| 1-3/week                              | 32.3                | 30.9                      | 29.3                        | 29.4            |         |
| ≥4/week                               | 11.6                | 10.7                      | 9.7                         | 11.2            |         |
| Hormone therapy after menopause:      |                     |                           |                             |                 | <0.001  |
| Never                                 | 49.4                | 38.7                      | 44.7                        | 46.0            |         |
| Past                                  | 8.7                 | 10.2                      | 8.5                         | 10.2            |         |
| Current                               | 41.9                | 51.2                      | 46.7                        | 43.8            |         |
| Family history of myocardial infarction before age 60 |         |                           |                             |                 | 0.09    |

Table 1 continued

| Characteristics                        | No migraine history | Active migraine with aura | Active migraine without aura | Prior migraine† | P value‡ |
|---------------------------------------|---------------------|---------------------------|-----------------------------|-----------------|---------|
| Never                                 | 51.2                | 52.4                      | 56.2                        | 50.5            | 0.03    |
| Past                                  | 37.0                | 37.3                      | 34.5                        | 35.5            |         |
| Current                               | 11.8                | 10.3                      | 9.3                         | 14.1            |         |
| History of hypertension§              | 24.7                | 25.6                      | 26.1                        | 30.5            | <0.001  |
| History of diabetes                   | 2.5                 | 1.8                       | 1.6                         | 2.6             | 0.23    |
| Mean (SE) BMI                         | 25.9 (0.03)         | 25.8 (0.13)               | 26.2 (0.11)                 | 26.1 (0.13)     | 0.02    |
| Alcohol consumption:                  |                     |                           |                             |                 |         |
| Rarely/never                          | 43.5                | 48.2                      | 47.4                        | 45.1            | <0.001  |
| 1-3 drinks/month                      | 13.1                | 12.9                      | 15.4                        | 14.3            |         |
| 1-6 drinks/week                       | 32.7                | 30.5                      | 30.0                        | 30.4            |         |
| ≥1 drink/day                          | 10.8                | 8.4                       | 7.2                         | 10.3            |         |
| Physical activity:                    |                     |                           |                             |                 | <0.001  |
| Rarely/never                          | 36.9                | 38.0                      | 39.4                        | 39.2            |         |
| <1/week                               | 19.2                | 20.4                      | 21.7                        | 20.2            |         |
| 1-3/week                              | 32.3                | 30.9                      | 29.3                        | 29.4            |         |
| ≥4/week                               | 11.6                | 10.7                      | 9.7                         | 11.2            |         |
| Hormone therapy after menopause:      |                     |                           |                             |                 | <0.001  |
| Never                                 | 49.4                | 38.7                      | 44.7                        | 46.0            |         |
| Past                                  | 8.7                 | 10.2                      | 8.5                         | 10.2            |         |
| Current                               | 41.9                | 51.2                      | 46.7                        | 43.8            |         |
| Family history of myocardial infarction before age 60 | 12.6               | 14.4                      | 13.0                        | 14.0            | 0.09    |

SE=standard error; HDL=high density lipoprotein; BMI=body mass index.

*Proportions might not add up to 100% because of rounding or missing values.
†Women who indicated history of migraine but no active migraine in year before completing baseline questionnaire.
‡From analysis of covariance for continuous variable or Mantel-Haenszel test for categorical variables.
§Defined as previous diagnosis of hypertension, systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or receipt of blood pressure lowering treatment at baseline.
the baseline questionnaire), of whom 1418 (39.6%) reported migraine aura.

Table 1 summarises the association between baseline characteristics according to migraine status. Compared with women without a history of migraine, women with active migraine with aura were younger, less likely to consume alcohol, less likely to exercise regularly, and more likely to currently use hormone therapy after the menopause. Women with prior migraine tended to have raised total cholesterol concentration and were more likely to currently smoke cigarettes, have higher systolic blood pressure, and to have a history of hypertension compared with the other migraine groups. Mean concentration of high density lipoprotein cholesterol was higher among women without a history of migraine. Family history of myocardial infarction was equally distributed among the migraine groups.

With regard to categories of the Framingham risk score, women who reported any history of migraine were more likely to have a higher predicted 10 year risk of coronary heart disease. Compared with women without a history of migraine and low estimated risk for coronary heart disease (≤1%), the age adjusted odds ratio of a predicted 10 year risk of coronary heart disease of ≥10% was 1.26 (95% confidence interval 1.06 to 1.49) for women who reported any history of migraine. After further stratification, this increased risk was apparent only in the group of migraineurs who indicated prior migraine (history of migraine but not active migraine) (1.83, 1.43 to 2.35) (table 2).

During a mean of 11.9 years of follow-up (326 547 person years), 697 participants had a first major ischaemic cardiovascular disease event, which, taking into account the potential for multiple events in a single individual, included 306 first ischaemic strokes, 301 first myocardial infarctions, and 148 deaths from cardiovascular disease. In addition, 647 underwent coronary revascularisation, and 412 reported angina during follow-up. The risk of major cardiovascular disease increased with increasing Framingham risk score. Compared with women with a predicted 10 year risk of coronary heart disease of ≤1%, the age adjusted hazard ratios for major cardiovascular disease were 3.11 (2.46 to 3.93), 6.04 (4.67 to 7.81), and 10.40 (7.76 to 13.94) for women with predicted risks of 2-4%, 5-9%, and ≥10%, respectively.

Active migraine with aura was associated with about a twofold increased risk of major cardiovascular disease, ischaemic stroke, and myocardial infarction (table 3). After stratification by Framingham risk score groups, the pattern of association between active migraine with aura and major cardiovascular disease was U shaped, with the highest estimate in the lowest risk score group. We observed a strikingly different pattern of association for the outcomes of ischaemic stroke and myocardial infarction (table 3, figure).

Compared with women without a history of migraine, the age adjusted hazard ratios for ischaemic stroke were 3.88 (1.87 to 8.08) in the lowest risk score group and 1.00 (0.24 to 4.14) for the highest. For myocardial infarction, these estimates were 1.29 (0.40 to 4.21) and 3.34 (1.50 to 7.46), respectively.

| Table 2 | Age adjusted association (odds ratio)* between migraine and Framingham predicted 10 year risk of coronary heart disease in 27519 women in women’s health study |
| --- | --- |
| | Framingham estimate of 10 year risk of coronary heart disease |
| | 2-4% | 5-9% | ≥10% |
| No history of migraine (n=22 445) | No of women | OR (95% CI) | P value | No of women | OR (95% CI) | P value | No of women | OR (95% CI) | P value |
| No history of migraine | 12 000 | 6912 | 1.00 (reference) | — | 2632 | 1.00 (reference) | — | 901 | 1.00 (reference) | — |
| History of migraine: | | | | | | | | | |
| Any (n=5074) | 2862 | 1487 | 1.09 (1.01 to 1.17) | 0.03 | 535 | 1.15 (1.03 to 1.29) | 0.02 | 190 | 1.26 (1.06 to 1.49) | 0.009 |
| Active migraine with aura (n=1418) | 840 | 393 | 1.02 (0.89 to 1.17) | 0.76 | 141 | 1.14 (0.94 to 1.40) | 0.19 | 44 | 1.14 (0.82 to 1.59) | 0.42 |
| Active migraine without aura (n=2159) | 1332 | 595 | 1.02 (0.92 to 1.14) | 0.72 | 178 | 1.00 (0.84 to 1.20) | 0.97 | 54 | 1.02 (0.76 to 1.36) | 0.92 |
| Prior migraine† (n=1497) | 690 | 499 | 1.27 (1.12 to 1.45) | <0.01 | 216 | 1.46 (1.22 to 1.75) | <0.01 | 92 | 1.83 (1.43 to 2.35) | <0.01 |

*Calculated from multinominal logistic regression model with women without history of migraine and with Framingham estimated 10 year risk of coronary heart disease ≤1% as reference group.
†Women with history of migraine but no active migraine in year before completing baseline questionnaire.
With regard to the association between active migraine with aura and coronary revascularisation, the hazard ratios were 1.58 (0.80 to 3.14), 1.70 (1.03 to 2.79), 0.93 (0.46 to 1.90), and 2.21 (1.11 to 4.40) for risk score groups ≤1%, 2-4%, 5-9%, and ≥10%, respectively. For angina, these estimates were 2.12 (1.01 to 4.45), 1.40 (0.68 to 2.88), 1.09 (0.48 to 2.50), and 2.06 (0.82 to 5.17).

When we evaluated the individual components of the Framingham risk score, the association between active migraine with aura and ischaemic stroke was particularly apparent for the younger age groups (45-54 and 55-64) and was not apparent among women aged ≥65 (table 4). The risk was further increased for women aged 45-49 (5.35, 2.08 to 13.79; P<0.001). With regard to systolic blood pressure, we found a greater risk of ischaemic stroke for women with low blood pressure. This trend was further magnified among women with systolic blood pressure <110 mm Hg (5.18, 1.70 to 15.80; P=0.004). Furthermore, the associated risk of ischaemic stroke for women with active migraine with aura increased with decreasing total cholesterol concentrations. When we evaluated lower cholesterol concentrations, women with migraine with aura and cholesterol <4.40 mmol/l had further increased risk (4.01, 1.15 to 13.96; P=0.03). This pattern was not driven by high density lipoprotein cholesterol (table 4). There was a U shaped pattern with regard to smoking, showing increased risk for current smokers and those who had never smoked, which reached significance for those who had never smoked.

Table 5 summarises the association between migraine and myocardial infarction stratified by individual components of the Framingham risk score. The association between active migraine with aura and myocardial infarction was increased in the age groups 45-54 and 55-64. In contrast with ischaemic strokes, however, there was no further increased risk when we evaluated the age group 45-49 (data not shown). With regard to systolic blood pressure, we found an increased risk of myocardial infarction for women with active migraine with aura who had values <120 mm Hg and ≥140 mm Hg. While the risk did not further increase in categories above 140 mm Hg (data not shown), the associated risk of myocardial infarction was strongest for women with active migraine with aura who had a systolic blood pressure <110 mm Hg (10.00, 2.96 to 33.77; P<0.001). In contrast with ischaemic stroke, the association between active migraine with aura and migraine with aura increased with increasing total cholesterol concentrations. The pattern of association between active migraine with aura and myocardial infarction according to category of smoking was similar to the findings for ischaemic stroke.

**DISCUSSION**

**Summary of findings**

In this large prospective cohort of women, the association between active migraine with aura and specific

---

**Table 3** | Age adjusted association (hazard ratio) between migraine and cardiovascular disease, stratified by Framingham estimate of 10 year risk of coronary heart disease* in 27 519 women in women’s health study

| Major cardiovascular event† | No of women | Active migraine with aura (n=1418) | Active migraine without aura (n=2159) | Prior migraine‡ (n=1497) |
|-----------------------------|-------------|-------------------------------------|--------------------------------------|-------------------------|
|                             |             | No of women | HR (95% CI) | P value | No of women | HR (95% CI) | P value | No of women | HR (95% CI) | P value |
| Overall                     | 557         | 53          | 1.93 (1.45 to 2.56) | <0.001 | 39          | 1.00 (0.72 to 1.38) | 0.98 | 48          | 1.23 (0.92 to 1.66) | 0.16 |
| Framingham risk group:      |             |             |             |         |             |             |         |             |             |         |
| ≤1%                         | 80          | 14          | 2.69 (1.52 to 4.75) | <0.001 | 9           | 1.09 (0.55 to 2.18) | 0.80 | 8           | 1.72 (0.83 to 3.57) | 0.14 |
| 2-4%                        | 204         | 16          | 1.60 (0.96 to 2.67) | 0.07   | 18          | 1.22 (0.75 to 1.99) | 0.42 | 11          | 0.74 (0.40 to 1.36) | 0.33 |
| 5-9%                        | 169         | 14          | 1.80 (1.04 to 3.11) | 0.04   | 9           | 0.87 (0.45 to 1.71) | 0.69 | 16          | 1.19 (0.71 to 1.98) | 0.51 |
| ≥10%                        | 104         | 9           | 1.93 (0.97 to 3.82) | 0.06   | 3           | 0.52 (0.17 to 1.66) | 0.27 | 13          | 1.32 (0.74 to 2.35) | 0.35 |
| Ischaemic stroke (n=306)    | 251         | 22          | 1.80 (1.16 to 2.79) | 0.008  | 17          | 0.99 (0.60 to 1.62) | 0.97 | 16          | 0.91 (0.55 to 1.50) | 0.70 |
| Framingham risk group:      |             |             |             |         |             |             |         |             |             |         |
| ≤1%                         | 36          | 9           | 3.88 (1.87 to 8.08) | <0.001 | 4           | 1.09 (0.39 to 3.07) | 0.87 | 3           | 1.44 (0.44 to 4.66) | 0.55 |
| 2-4%                        | 94          | 6           | 1.34 (0.59 to 3.07) | 0.48   | 9           | 1.39 (0.70 to 2.77) | 0.35 | 3           | 0.44 (0.14 to 1.38) | 0.16 |
| 5-9%                        | 77          | 5           | 1.41 (0.57 to 3.51) | 0.46   | 2           | 0.43 (0.11 to 1.75) | 0.24 | 8           | 1.30 (0.63 to 2.70) | 0.48 |
| ≥10%                        | 44          | 2           | 1.00 (0.24 to 4.14) | 0.99   | 2           | 0.96 (0.23 to 4.00) | 0.95 | 2           | 0.49 (0.12 to 2.02) | 0.32 |
| Myocardial infarction (n=301)| 240         | 24          | 1.94 (1.27 to 2.95) | 0.002  | 17          | 0.95 (0.58 to 1.56) | 0.85 | 20          | 1.20 (0.76 to 1.89) | 0.44 |
| Framingham risk group:      |             |             |             |         |             |             |         |             |             |         |
| ≤1%                         | 35          | 3           | 1.29 (0.40 to 4.21) | 0.67   | 4           | 1.10 (0.39 to 3.09) | 0.86 | 3           | 1.48 (0.45 to 4.80) | 0.52 |
| 2-4%                        | 83          | 8           | 1.87 (0.90 to 3.88) | 0.09   | 9           | 1.41 (0.71 to 2.83) | 0.33 | 5           | 0.83 (0.34 to 2.04) | 0.68 |
| 5-9%                        | 79          | 6           | 1.58 (0.69 to 3.65) | 0.28   | 3           | 0.60 (0.19 to 1.92) | 0.39 | 6           | 0.94 (0.41 to 2.16) | 0.89 |
| ≥10%                        | 43          | 7           | 3.34 (1.50 to 7.46) | 0.003  | 1           | 0.35 (0.05 to 2.54) | 0.30 | 6           | 1.36 (0.58 to 3.20) | 0.48 |

*Women in each risk group: 14 862 in ≤1%; 8399 in 2-4%; 3167 in 5-9%; 1091 in ≥10%.

**Hazard ratio=1.**

**History of migraine but no active migraine in year before completion of baseline questionnaire.**

**Defined as first of any of: non-fatal ischaemic stroke, non-fatal myocardial infarction, or death from ischaemic cardiovascular cause.**
Table 4 | Age adjusted association (hazard ratio) between migraine and ischaemic stroke, stratified by components of Framingham risk score in 27,519 women in women’s health study

| Age (years):          | No of women | HR (95% CI) | No of women | HR (95% CI) | No of women | HR (95% CI) | No of women | HR (95% CI) | P value |
|-----------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|---------|
| ≥55-64 (n=16444)     | 64          | 2.59 (1.40 to 4.80) | 0.003       | 8           | 1.07 (0.51 to 2.24) | 0.85       | 2           | 0.51 (0.12 to 2.07) | 0.34    |
| ≤55 (n=8160)         | 91          | 2.13 (1.07 to 4.23) | 0.03        | 5           | 0.79 (0.32 to 1.95) | 0.61       | 8           | 1.19 (0.58 to 2.46) | 0.63    |
| ≥65 (n=2915)         | 96          | 0.32 (0.04 to 2.29) | 0.26        | 4           | 1.28 (0.47 to 3.49) | 0.63       | 6           | 0.85 (0.37 to 1.93) | 0.69    |

Systolic blood pressure (mm Hg):
| ≤120 (n=12389)      | 55          | 3.42 (1.74 to 6.75) | <0.001      | 3           | 0.69 (0.22 to 2.22) | 0.54       | 4           | 1.21 (0.44 to 3.34) | 0.71    |
| 120-139 (n=11678)   | 102         | 1.18 (0.52 to 2.69) | 0.69        | 10          | 1.47 (0.76 to 2.84) | 0.25       | 7           | 0.93 (0.43 to 2.00) | 0.85    |
| ≥140 (n=3452)       | 94          | 1.49 (0.65 to 3.42) | 0.34        | 4           | 0.65 (0.24 to 1.77) | 0.40       | 5           | 0.67 (0.27 to 1.65) | 0.39    |

Smoking:
| Never (n=14219)     | 104         | 2.31 (1.23 to 4.32) | 0.009       | 8           | 1.12 (0.54 to 2.32) | 0.76       | 4           | 0.54 (0.20 to 1.45) | 0.22    |
| Past (n=10100)      | 98          | 1.23 (0.54 to 2.82) | 0.62        | 5           | 0.82 (0.33 to 2.03) | 0.67       | 6           | 0.89 (0.39 to 2.04) | 0.79    |
| Current (n=3200)    | 49          | 2.10 (0.84 to 5.30) | 0.11        | 4           | 1.25 (0.45 to 3.47) | 0.67       | 6           | 1.63 (0.70 to 3.81) | 0.26    |

Total cholesterol (mmol/l):
| ≤5.17 (n=11171)     | 58          | 3.29 (1.68 to 6.45) | <0.001      | 9           | 2.18 (1.07 to 4.44) | 0.03       | 7           | 1.85 (0.84 to 4.05) | 0.12    |
| 5.17-6.20 (n=10292) | 106         | 1.08 (0.44 to 2.65) | 0.87        | 4           | 0.58 (0.21 to 1.58) | 0.29       | 4           | 0.58 (0.21 to 1.57) | 0.28    |
| ≥6.21 (n=6056)      | 87          | 1.56 (0.72 to 3.38) | 0.26        | 4           | 0.65 (0.24 to 1.77) | 0.39       | 5           | 0.69 (0.28 to 1.70) | 0.42    |

HDL cholesterol (mmol/l):
| ≤1.01 (4763)        | 60          | 1.56 (0.63 to 3.90) | 0.34        | 7           | 1.55 (0.70 to 3.42) | 0.28       | 6           | 1.33 (0.57 to 3.07) | 0.51    |
| 1.03-1.54 (n=14536) | 121         | 2.19 (1.23 to 3.89) | 0.008       | 5           | 0.61 (0.25 to 1.49) | 0.28       | 7           | 0.81 (0.38 to 1.74) | 0.60    |
| ≥1.55 (n=8221)      | 70          | 1.27 (0.46 to 3.48) | 0.64        | 5           | 1.12 (0.45 to 2.79) | 0.81       | 3           | 0.61 (0.19 to 1.95) | 0.41    |

HDL = high density lipoprotein.
*Hazard ratio=1.
†History of migraine but no active migraine in year before completion of baseline questionnaire.

We have previously shown that the association between migraine with aura and cardiovascular disease in the women’s health study remains significant even after adjustment for major cardiovascular risk factors. Our data add to the growing evidence that migraine is associated with increased risk of vascular events and that the risk of specific cardiovascular disease outcomes might depend on the presence or absence of vascular risk factors. Our results are of interest for general practitioners as a history of migraine in combination with information on vascular risk status, as measured by the Framingham risk score, could indicate future cardiovascular disease events. This is analogous to recent work indicating that a history of pre-eclampsia is a risk factor for cardiovascular disease in later life. Our data imply that among patients with migraine, cardiovascular risk factors should be more carefully sought and controlled.

Results of the genetic epidemiology of migraine study suggest that migraine, particularly migraine with aura, is associated with increased likelihood of an unfavourable cardiovascular risk profile and a high Framingham risk score. Compared with participants without migraine and predicted risk (according to the Framingham risk score) for coronary heart disease of <1%, migraineurs with aura had too few participants with very high Framingham risk predicted 10 year risk of coronary heart disease (according to the Framingham risk score), this association did not differ with regard to migraine aura status. We had too few participants with very high Framingham risk.
scores, however, to allow us to evaluate the association between migraine and 10 year risk prediction for coronary heart disease of ≥21%.

**Potential biological mechanisms**

Recent studies on the pathophysiology of migraine suggest that migraine can also be viewed in part as a systemic disorder that is affecting the vasculature, and migraineurs might have reduced number and function of endothelial progenitor cells, a surrogate for marker for impaired vascular function. Even in the absence of vascular risk factors, people with migraine have decreased cerebral21 and peripheral vascular resistance22 and increased likelihood of retinal microvascular signs,23 hypercoagulability,24 and inflammation.25 Moreover, the altered vascular reactivity is already present among young patients with a recent onset of migraine (mean age 24.6).26

Findings from previous studies have suggested that the association between migraine with aura and ischaemic stroke is more apparent for individuals without vascular risk factors27 with the exception of smoking and use of oral contraceptives in women.28 In particular, people with migraine and no history of hypertension or diabetes had increased risk of ischaemic stroke.29 People with migraine also have a higher likelihood of retinal microvascular signs.26 Furthermore, the proportion of ischaemic strokes among patients with migraine is less likely to be of atherosclerotic origin,26 and, specifically, ischaemic strokes in the posterior circulation of migraineurs are probably caused by microembolism and hyperfusion.29 The increased risk of ischaemic stroke for migraineurs with aura in the lowest Framingham risk score group seen in our study supports these findings. Because the score is composed of traditional risk factors for cardiovascular disease, it can be interpreted as a proxy for vascular health. Thus, it is plausible that the biological mechanisms by which migraine with aura results in ischaemic vascular events in the brain require a vasculature not altered by atherosclerosis but might involve microvascular changes.

Several studies have found an association between migraine with aura and angina but not myocardial infarction.30 In addition, patients with active migraine with chest symptoms or suspected coronary ischaemia had lower angiographic coronary severity scores than patients with similar symptoms but no migraine.30 In our data, the association between migraine with aura and angina was increased for patients in the low and high risk score groups. Furthermore, our data indicate that the association between migraine with aura and myocardial infarction is apparent only among patients with a high Framingham risk score. Thus, the effect of migraine with aura on the coronary arteries might involve two mechanisms, one involving a vasculature not altered by atherosclerosis leading to angina and one involving a vasculature impaired by atherosclerosis leading to angina and myocardial infarction. Moreover, as

---

Table 5: Age adjusted association (hazard ratio) between migraine and myocardial infarction, stratified by components of Framingham risk score in 27 519 women in women’s health study

| Age (years): | Active migraine with aura (n=1418) | Active migraine without aura (n=2159) | Previous migraine† (n=1497) |
|-------------|-----------------------------------|--------------------------------------|----------------------------|
| 45-54 †(n=16 444) | 65 | 10 | 2.10 (1.08 to 4.09) 0.03 | 7 | 0.92 (0.42 to 2.00) 0.83 | 7 | 1.75 (0.81 to 3.83) 0.16 |
| 55-64 †(n=8160) | 109 | 11 | 2.09 (1.12 to 3.90) 0.02 | 9 | 1.16 (0.58 to 2.28) 0.68 | 5 | 0.62 (0.25 to 1.52) 0.30 |
| 65 †(n=2915) | 66 | 3 | 1.39 (0.44 to 4.42) 0.58 | 1 | 0.46 (0.06 to 3.28) 0.43 | 8 | 1.65 (0.79 to 3.45) 0.18 |

Systolic blood pressure (mm Hg):
| <120 (n=12 389) | 38 | 7 | 3.53 (1.57 to 7.95) 0.002 | 4 | 1.37 (0.48 to 3.84) 0.56 | 1 | 0.44 (0.06 to 3.17) 0.41 |
| 120-139 (n=11 678) | 135 | 10 | 1.33 (0.70 to 2.53) 0.39 | 11 | 1.01 (0.54 to 1.87) 0.99 | 12 | 1.21 (0.67 to 2.18) 0.54 |
| ≥140 (n=3452) | 67 | 7 | 2.45 (1.12 to 5.36) 0.03 | 2 | 0.45 (0.11 to 1.83) 0.26 | 7 | 1.34 (0.61 to 2.91) 0.46 |

Smoking:
| Never (n=14 219) | 78 | 11 | 2.82 (1.49 to 5.32) 0.001 | 7 | 1.16 (0.53 to 2.53) 0.71 | 9 | 1.64 (0.82 to 3.27) 0.16 |
| Past (10 100) | 94 | 6 | 1.26 (0.55 to 2.88) 0.59 | 7 | 1.16 (0.53 to 2.51) 0.71 | 5 | 0.78 (0.32 to 1.91) 0.58 |
| Current (n=3200) | 68 | 7 | 2.08 (0.95 to 4.55) 0.07 | 3 | 0.65 (0.20 to 2.06) 0.46 | 6 | 1.17 (0.51 to 2.69) 0.72 |

Total cholesterol (mmol/l):
| <5.17 (n=11 171) | 61 | 4 | 1.24 (0.45 to 3.41) 0.68 | 3 | 0.69 (0.21 to 2.20) 0.52 | 7 | 1.77 (0.81 to 3.87) 0.15 |
| 5.17-6.20 (n=10 292) | 90 | 7 | 1.54 (0.71 to 3.34) 0.27 | 9 | 1.33 (0.66 to 2.65) 0.42 | 7 | 1.19 (0.55 to 2.56) 0.66 |
| ≥6.21 (n=6056) | 89 | 13 | 2.71 (1.51 to 4.86) <0.001 | 5 | 0.73 (0.30 to 1.80) 0.49 | 6 | 0.82 (0.36 to 1.89) 0.65 |

HDL cholesterol (mmol/l):
| <1.03 (4762) | 82 | 8 | 1.71 (0.83 to 3.55) 0.15 | 8 | 1.14 (0.55 to 2.38) 0.72 | 8 | 1.27 (0.62 to 2.63) 0.52 |
| 1.03-1.54 (n=14 536) | 123 | 12 | 1.94 (1.07 to 3.52) 0.03 | 8 | 0.93 (0.45 to 1.91) 0.85 | 7 | 0.81 (0.38 to 1.72) 0.58 |
| ≥1.55 (n=8221) | 35 | 4 | 2.44 (0.86 to 6.88) 0.09 | 1 | 0.42 (0.06 to 3.11) 0.40 | 5 | 2.07 (0.81 to 5.28) 0.13 |

HDL-high density lipoprotein.
*Hazard ratio 1.
†History of migraine but no active migraine in year before completion of baseline questionnaire.
Information on history of migraine and vascular risk status might help to identify women at increased risk for specific future cardiovascular disease events.

**Migraine with aura is associated with increased risk of ischaemic stroke only among women with high vascular risk scores**

Migraine with aura is associated with increased risk of ischaemic stroke only among women with high vascular risk scores.

**WHAT THIS STUDY ADDS**

The Framingham risk score for coronary heart disease is a measure of vascular risk. The Framingham risk score is a tool used to predict the risk of a cardiovascular event, such as a heart attack, within the next 10 years. A higher Framingham risk score indicates a greater risk for cardiovascular disease.

The Framingham risk score is calculated using factors such as age, gender, blood pressure, cholesterol levels, smoking status, and family history of cardiovascular disease. People with a high Framingham risk score are considered to be at increased risk for cardiovascular disease.

**Strengths and weaknesses of study**

Our study has several strengths, including the prospective design, large number of participants and outcome events, long follow-up and participation rate, standardised evaluation of migraine and cardiovascular disease risk factors, confirmed cardiovascular disease events by an end points committee of physicians, and the homogeneous nature of the cohort, which could reduce confounding.

Several limitations should be also considered when interpreting our results. Firstly, migraine and migraine aura status were self reported leading to potential misclassification. Because of the prospective design, however, any misclassification would probably result in underestimation of relative risks and would be unlikely to explain the observed association pattern. Furthermore, we have previously reported that our migraine classification had good agreement with 1988 IHS criteria and our prevalence of migraine and migraine aura is close to that reported in other population based studies.

Secondly, we had no detailed information on use of specific drugs for migraine that might be associated with ischaemic events. Such drugs, however, tend to be used by all migraineurs, not just those with migraine aura. Furthermore, the different pattern of association between migraine with aura and ischaemic stroke and myocardial infarction according to vascular risk status can hardly be explained by drug use. Thirdly, despite the overall high number of outcome events, this number was small when we stratified by migraine and Framingham risk score categories. Fourthly, our stratified analyses are adjusted only for age and not other major cardiovascular disease risk factors. We have previously shown, however, that the association between migraine with aura and cardiovascular disease in this cohort is independent of major risk factors for cardiovascular disease.

In addition, inclusion of major risk factors for cardiovascular disease as well as randomised treatment assignments in the stratified models showed similar associations (data not shown). Residual confounding remains a potential alternative explanation as our data are observational. Finally, participants in the women’s health study were all health professionals aged ≥45 and mostly white, thus generalisability might be limited. We have no reason to believe that the biological mechanisms by which migraine with aura might be associated with vascular events would be different in other populations of women.

**Conclusions**

Results from this large prospective study of women indicate that information on vascular risk status might help to identify women with migraine with aura who are at a particularly increased risk for specific future cardiovascular disease events with a diametric pattern of association for ischaemic stroke and myocardial infarction. Physicians should consider evaluating vascular risk factors in patients with migraine with aura.

We thank the participants in the women’s health study for their outstanding commitment and cooperation and all the staff for their expert and unfailing assistance.

**Contributors:** TK conceived and designed the study, analysed the data, and drafted the manuscript. JEB was responsible for the acquisition of the data. All authors interpreted the data, critically revised the draft for important intellectual content, and gave final approval of the version to be published. TK is guarantor.

**Funding:** The women’s health study is supported by grants and from the National Heart, Lung, and Blood Institute (HL-043851 and HL-080467), and the National Cancer Institute (CA-47988). The research for this work was supported by grants from the Donald W Reynolds Foundation, the Leducq Foundation, and the Doris Duke Charitable Foundation.

**Competing interests:** TK has received funding from the National Institutes of Health, Bayer AG, McNeil Consumer and Specialty Pharmaceuticals, and Wyeth Consumer Healthcare; he is a consultant to 3 Drug Safety, and received an honorarium from Organon for contributing to an expert panel. MS has received funding from the Deutsche Forschungsgemeinschaft and an unrestricted research grant from Merck, Sharp and Dohrme. GL has received funding from the National Institutes of Health and received honoraria from Pfizer and Lilly Pharmaceutical for speaking engagements in 2003. JMC has received funding and support from National Institutes of Health, BASF, DSM Pharmaceuticals, Wyeth Pharmaceuticals, McNeil Consumer Products and Pliva; received honoraria from Bayer and Pfizer for speaking engagements, and is a consultant for Bayer, McNeil Consumer Products, Wyeth Pharmaceuticals, Merck, Nutraquest, and GlaxoSmithKline. JEB has received funding and support from the National Institutes of Health, Bayer AG, McNeil Consumer and Specialty Pharmaceuticals, and the Natural Source Vitamin E Association, and an honorarium from Bayer for speaking engagements.

**Ethical approval:** Institutional review board of Brigham and Women’s Hospital, Boston, MA USA.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

1. Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med 2005;118(Suppl 1):S3-10.
17 Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women’s Health Study. J Women’s Health Gend Based Med 2000;9:19-27.

18 Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.

19 Bensenor IM, Cook NR, Lee IM, Chown MI, Hennekens CH, Buring JE. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 2001;21:175-83.

20 Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(Suppl 7):1-96.

21 Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.

22 Atya M, Kurfth, Berger K, Buring JE, Kase CS. Interobserver agreement in the classification of stroke in the women’s health study. Stroke 2003;34:565-7.

23 Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974.

24 Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN, et al. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 2008;70:1510-7.

25 Totaro R, Marinii C, De Matteis G, Di Napoli M, Carolei A. Cerebrovascular reactivity in migraine during headache-free intervals. Cephalalgia 1997;17:191-4.

26 Tietjen GE, Al-Qasmi MM, Athanas K, Utley C, Heria NA. Altered hemostasis in migraineurs studied with a dynamic flow system. Thromb Res 2007;119:217-22.

27 Longoni M, Ferrari C. Inflammation and excitotoxicity: role in migraine pathogenesis. Neurol Sci 2006;27(suppl 2):S107-10.

28 Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine: the population-based MRI camera study. Brain 2005;128:2068-77.

29 Ahmed B, Bairey Merz CN, McClure C, Johnson BD, Reis SE, Bittner V, et al. Migraines, angiographic coronary artery disease, and cardiovascular outcomes in women. Am J Med 2006;119:670-5.

30 Kurfth, Ridker PM, Buring JE. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 2008;28:49-56.

31 Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American migraine study II. Headache 2001;41:638-45.

32 Launder LJ, Tendrich GM, Ferreri MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-42.

Accepted: 27 May 2008